Your browser doesn't support javascript.
loading
Development and validation of fear of hypoglycemia screener: results from the T1D exchange registry.
Liu, Jingwen; Poon, Jiat-Ling; Bispham, Jeoffrey; Perez-Nieves, Magaly; Hughes, Allyson; Chapman, Katherine; Mitchell, Beth; Hood, Korey; Snoek, Frank; Fisher, Lawrence.
Afiliación
  • Liu J; T1D Exchange, Boston, MA, USA.
  • Poon JL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Bispham J; T1D Exchange, Boston, MA, USA.
  • Perez-Nieves M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Hughes A; T1D Exchange, Boston, MA, USA.
  • Chapman K; T1D Exchange, Boston, MA, USA.
  • Mitchell B; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. mitchell_beth_d@lilly.com.
  • Hood K; Stanford University School of Medicine, Stanford, CA, USA.
  • Snoek F; Department of Medical Psychology Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Fisher L; Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA, USA.
J Patient Rep Outcomes ; 7(1): 43, 2023 05 09.
Article en En | MEDLINE | ID: mdl-37160500
ABSTRACT

BACKGROUND:

Fear of Hypoglycemia (FoH) in people with diabetes has a significant impact on their quality of life, psychological well-being, and self-management of disease. There are a few questionnaires assessing FoH in people living with diabetes, but they are more often used in research than clinical practice. This study aimed to develop and validate a short and actionable FoH screener for adults living with type 1 diabetes (T1D) for use in routine clinical practice.

METHODS:

We developed an initial screener based on literature review and, interviews with healthcare providers (HCPs) and people with T1D. We developed a cross-sectional web-based survey, which was then conducted to examine the reliability and validity of the screener. Adults (aged ≥ 18 years) with diagnosis of T1D for ≥ 1 year were recruited from the T1D Exchange Registry (August-September 2020). The validation analyses were conducted using exploratory factor analyses, correlation, and multivariable regression models for predicting cut-off scores for the final screener.

RESULTS:

The final FoH screener comprised nine items assessing two domains, "worry" (6-items) and "avoidance behavior" (three items), in 592 participants. The FoH screener showed good internal consistency (Cronbach's α = 0.88). The screener also demonstrated high correlations (r = 0.71-0.75) with the Hypoglycemia Fear Survey and moderate correlations with depression, anxiety, and diabetes distress scales (r = 0.44-0.66). Multivariable regression analysis showed that higher FoH screener scores were significantly associated with higher glycated hemoglobin (HbA1c) (b = 0.04) and number of comorbidities (b = 0.03).

CONCLUSIONS:

This short FoH screener demonstrated good reliability and validity. Further research is planned to assess clinical usability to identify patients with FoH and assist effective HCP-patient conversations.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Hipoglucemia Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: J Patient Rep Outcomes Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Hipoglucemia Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: J Patient Rep Outcomes Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos